期刊文献+

碎石术辅助白拟排石方对合并膀胱结石的良性前列腺增生患者下尿路症状的改善作用 被引量:6

To improve the effect of Chinese herbal decoction on patients with benign prostatic hyperplasia complicated with bladder stones of lower urinary tract symptoms after lithotripsy of bladder
原文传递
导出
摘要 目的探讨碎石术辅助自拟排石方对合并膀胱结石的良性前列腺增生(benign prostatic hyperplasia,BPH)患者下尿路症状的改善作用。方法纳入72例BPH合并膀胱结石的患者并按病历尾号随机分为辅助治疗组(35例)和非辅助治疗组(37例)。非辅助治疗组于碎石术后膀胱持续冲洗1周,口服坦索罗辛与非那雄胺片1周;辅助治疗组在碎石术术前2d开始服用自拟排石方,共2周。检测和评价治疗前后最大尿流率(maximum urinary flow rate,Qmax)、残留尿量(residual urine volume,RU)以及国际前列腺症状评分(International Prostate SymptomScore,IPSS)和生活质量(Quality of Life,QOL)。比较2组尿常规恢复正常和尿管留置时间。半年后随访尿瘘、尿失禁和膀胱结石复发。结果治疗后,辅助治疗组1PSS评分[(12.9±4.5)分比(15.7±3.9)分;t=2.826,P=0.006]和RU[(47.3±9.2)ml比(58.4±11.3)ml;t=4.556,P〈0.001]显著低于非辅助治疗组,Qmax显著高于非辅助治疗组[(30.4±4.7)ml/s比(21.4±3.9)ml/s;t=8.862,P〈0.001]。辅助治疗组尿管留置时间[(5.7±2.1)d比(8.1±2.2)d;t=4.730,P〈0.001]和尿常规恢复时间[(6.9±2.3)d比(10.2±3.1)d;t=5.106,P〈0.001]均较非辅助治疗组显著缩短。随访6个月显示辅助治疗组尿失禁发生率[2.9%(1/35)比18.9%(7/37);x2=4.698,P=0.030]和结石复发率[5.7%(2/35)比24.3%(9/37);x2=4.813,P=0.028]均显著低于非辅助治疗组。辅助治疗组总有效率显著高于非辅助治疗组[62.9%(22/35)比29.7%(11/37);x2=6.672,P=0.011]。结论碎石术辅助白拟排石方治疗可降低合并膀胱结石的BPH患者IPSS评分和RU,提高Qmax,减少尿失禁和膀胱结石复发,改善下尿路症状。 Objective To evaluate the improvement of lower urinary tract symptoms in benign prostatic hyperplasia (BPH) patients with bladder calculi by lithotripsy and adjuvant traditional Chinese decoction. Methods A total of 72 BPH patients with bladder calculi were recruited and randomly divided into the non-adjuvant treatment group (37 patients) and the adjuvant treatment group (35 patients). The adjuvant treatment group received adjuvant traditional Chinese decoction from 2 days before lithotripsy for 2 weeks. The maximum urinary flow rate (Qmax), residual urine volume (RU), International Prostate Symptom Score (IPSS) and Quality of Life (QOL) were assessed before and after the treatment. The time of urine routine returned to normal and the indwelling time of catheter were compared between two groups. Urinary incontinence and recurrent bladder calculi were followed up for 6 months. Results After the treatment, the score of the IPSS (12.9 ± 4.5 vs. 15.7 ± 3.9; t=-2.826, P=0.006) and the RU (47.3 ± 9.2 ml vs. 58.4 ± 11.3 ml; t=4.556, P〈0.001) in the adjuvant treatment group were significantly lower than those in the non-adjuvant treatment group, and the Qmax (30.4 ± 4.7 ml/s vs. 21.4 ± 3.9 ml/s; t=8.862, P〈0.001 ) was significantly higher. The indwelling time of catheter (5.7 ± 2.1 d vs. 8.1 ± 2.2d; t=4.730, P〈0.001) and the time of urine routine returned to normal (6.9 ± 2.3 d vs. 10.2 ± 3.1 d; t=5.106, P〈0.001) in the adjuvant treatment group were significantly shorter than those in the non-adjuvant treatment group. The 6-month follow-up showed that the incidence of urinary incontinence (2.9% vs. 18.9%; x2=4.698, P=0.030) and recurrent bladder calculi (5.7% vs. 24.3%; x2=4.813, P=0.028) in the adjuvant treatment group were significantly shorter than those in the non-adjuvant treatment group, and the total effective rate was significantly higher (62.9% vs. 29.7%; X2=6.672, P=0.011). Conclusions Lithotripsy and adjuvant traditional Chinese decoction can reduce the IPSS score and RU, increase Qrnax, decrease urinary incontinence and recurrent bladder calculi, and improve lower urinary tract symptoms in BPH patients with bladder calculi. [Key words] Prostatic hyperplasia; Urinary bladder calculi; Lower urinary tract symptoms; Lithotripsy; Drugs, Chinese herbal
出处 《国际中医中药杂志》 2016年第2期114-117,共4页 International Journal of Traditional Chinese Medicine
关键词 前列腺增生 膀胱结石 下尿路症状 碎石术 中草药 Prostatic hyperplasia Urinary bladder calculi Lower urinary tract symptoms Lithotripsy Drugs, Chinese herbal
  • 相关文献

参考文献8

  • 1Papatsoris AG, Varkarakis I, DeUis A, et al. Bladder lithiasis from open surgery to lithotripsy [J]. Urol Res, 2006, 34 (3) : 163-167.
  • 2Mill6n-Rodrlguez F, Errando-Smet C, Rousaud-Bar6n F, et al. Urodynamic findings before and after noninvasive management of bladder calculi[J]. BJU hat, 2004, 93 (9) : 1267-1270.
  • 3张祥华,王行环,王刚,魏强,许传亮,薛蔚,严维刚,杨家荣,朱刚,孙颖浩,叶章群,孙则禹,那彦群.良性前列腺增生临床诊治指南[J].中华外科杂志,2007,45(24):1704-1707. 被引量:232
  • 4AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1 :Diagnosis and treatment recommendations[J]. J Urol, 2003, 170 (2/1) : 530-547.
  • 5Alan McNeill S. The role of alpha-blockers in the management of acute urinary etention caused by benign prostatic obstruction[J]. Eur Urol, 2004, 45 (3) : 325-332.
  • 6MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects [J]. Urology, 2005, 66 (4) : 780-788.
  • 7Andriole G, Bmchovsky N, Chung LW, et al. Dilaydrotestosterone and the prostate:the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia[J]. J Urol, 2004, 172 (4/1) : 1399-1403.
  • 8Ftlllhase C, Chapple C, Comu JN, et al. Systematic review of combination drug therapy for uon-nenrogenic male lower urinary tract symptoms[J]. Eur Urol, 2013, 64(2) :228-243. DOI: 10. 1016/j. eururo.2013.01.018.

二级参考文献25

  • 1洪宝发,蔡伟,符伟军,杨勇,王威,陈耀富,展洁,张翠娥,李炎唐,崔胜堂.选择性绿激光汽化术治疗良性前列腺增生的临床研究[J].中华泌尿外科杂志,2005,26(1):17-19. 被引量:90
  • 2郭利君,张祥华,李培军,那彦群.良性前列腺增生与原发性高血压的相关性研究[J].中华外科杂志,2005,43(2):108-111. 被引量:59
  • 3Rowhrborm CG, McConnell JD. Etiology, pathothysiology, epidemiology and natural history of binign prostatic hyperplasia// Campbell' s Urology. Philadelphia: Saunders Company, 2002 : 1297-1330.
  • 4Meigs JB, Barry MJ, Giovannucci E, et al. Incidence rates and risk factors for acute urinary retention: the health professionals follow up study. J Urol, 1999, 162:376-382.
  • 5Rule AD, Laeber MM, Jacobsen SJ, et al. Is benign prostatic hyperplasia a risk factor for chronic renal failure? J Urol, 2005, 173:691-696.
  • 6McConnell JD, Roehrborn CG, Baustita OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 2003, 349:2387-2398.
  • 7Jacobsen SJ, Jacobson DJ, Girman C J, et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol, 1999, 162:1301-1306.
  • 8Roehrbohn CG, McConnell JD, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia: PLESS study. J Urol, 2000, 163:13-20.
  • 9Bhargava S, Canda AE, Chapple CR. A rational approach to benign prostatic hyperplasia evaluation: recent advances. Curr Opin Urol, 2004, 14: 1-6.
  • 10Netto JH, de Lima ML, Netto MR, et al. Evaluation of patients with bladder outlet obstruction and mild intemational prostate symptom score followed up by watchful waiting. Urology, 1999, 53:314-316.

共引文献231

同被引文献52

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部